Cross-border tumor boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024.